Skip to main content
. 2018 Jan 13;9(11):10029–10041. doi: 10.18632/oncotarget.24252

Figure 6. CD44s plays an important role in TGB-β1-mediated EMT in CDDP resistant oral cancer cells.

Figure 6

(A) Schematic representation of tetracycline inducible CD44s knockdown in SAS-5.1 cells. CD44s was first knock-downed by tetracycline (TET) treatment (2 μg/ml) for 96 h in SAS-5.1 ishCD44 cells, and then EMT was induced by TGF-β1 treatment for 96 h under CD44s knockdown conditions. (B) The expression of RFP and non-targeting shRNA or shRNA against CD44s was induced by TET treatment (2 μg/ml) in SAS-5.1 ishNC cells (Left panel). (C) The expression levels of CD44s and E-cad were evaluated in SAS-5.1 ishNC cells after TET (2 μg/ml) and TGF-β1 treatment (5 ng/ml) (Right panel). The expression of RFP and non-targeting shRNA or shRNA against CD44s was induced by TET treatment (2 μg/ml) in SAS-5.1 ishCD44s cells (Left panel). The expression levels of CD44s and E-cad were evaluated in SAS-5.1 ishCD44s cells after TET (2 μg/ml) and TGF-β1 treatment (5 ng/ml) (Right panel).